Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Gastrointestinal 1

Conditions

Neoplasms 2Breast Neoplasms 2Pancreatic Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Leukemia, Myeloid, Acute 1Gallbladder Neoplasms 1Colorectal Neoplasms 1Cholangiocarcinoma 1

Interventions

Gemcitabine 20Cisplatin 17pembrolizumab 11Magnetic Resonance Spectroscopy 7durvalumab 5Platinum 5Irinotecan 5Fluorouracil 51,2-diaminocyclohexaneplatinum II citrate 5Leucovorin 4Taxes 3Oxaliplatin 3Nivolumab 3Fluorodeoxyglucose F18 3Carboplatin 3Biopsy 3Bevacizumab 3spartalizumab 2pemigatinib 2ivosidenib 2fludarabine 2budigalimab 2atezolizumab 2Specimen Handling 2Radiosurgery 2Paclitaxel 2Immunoglobulin G 2Floxuridine 2FAPI-46 2Disulfides 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Cholangiocarcinoma × merestinib × Clear all
NCT03027284 2020-05-19

A Study of Merestinib (LY2801653) in Japanese Participants With Advanced or Metastatic Cancer

Eli Lilly and Company

Phase 1 Completed
19 enrolled
GastrointestinalLymphoid

Gallbladder Neoplasms, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡